Esperite (ESP), The Cell Factory presents pre-clinical results on the new products of the 2nd generation EV’s drugs for treatment of inflammatory diseases
March 29, 2018
Group News
Esperite with its biotech company The Cell Factory has acquired from OPBG the full rights to the IP and the international patent family covering the invention and the therapeutic use of the EV’s products. In collaboration with Women’s and Children’s Health Department of the University of Padua, Italy they are presenting the new generation EV’s biologic drugs bio-activated with Annexin V targeting multiple inflammatory diseases i.e.: Crohn’s disease, drug resistance epilepsy, stroke. The experimental results will be presented during GISM congress in Assisi, Italy in April and ISEV meeting in Barcelona, Spain in May 2018.
Amsterdam, the Netherlands – 29 March 2018
